A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Conclusion: Apixaban 2.5 mg BID demonstrated less intersubject variability in exposure, lower AXA AUC, and higher trough and smaller peak-to-trough fluctuations in plasma concentration and AXA, suggesting more constant anticoagulation compared with rivaroxaban 10 mg QD. However, the clinical impact of these differences on the relative efficacy and safety of apixaban and rivaroxaban remains to be determined. Keywords: apixaban, pharmacodynamics, pharmacokinetics, rivaroxaban, safetyA letter to the Editor has been received and published for this article.
Source: International Journal of COPD - Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research